Introduction {#Sec1}
============

Sleep apnea (SA), namely, is the absence of oronasal air flow during sleep. The pathophysiologic characteristics of SA are chronic intermittent hypoxia and sleep fragmentation \[[@CR1]\]. SA is a highly prevalent disorder among adults \[[@CR2]\]. SA is divided to obstructive sleep apnea (OSA) and central sleep apnea (CSA). The former is characterized by recurrent collapse of upper airway, whereas the latter is caused by the unstable ventilation drive \[[@CR1], [@CR3]\]. Abundant evidence confirmed that SA is firmly associated with increased risk of cardiovascular disease and mortality \[[@CR4], [@CR5]\]. Studies also suggested that SA might influence the levels of hematocrit \[[@CR6]\] and blood viscosity \[[@CR7]\]. The correlation between SA and polycythemia has also been reported \[[@CR8]\].

Erythropoietin (EPO) is a glycoprotein hormone which is synthesized primarily by the kidney in adult. It is widely recognized that EPO may stimulate erythroid stem cells of the bone marrow to proliferate and differentiate. EPO has also been identified to play an important role in the mechanism of cardiovascular diseases. Robust evidence shows that EPO appears to be released in response to hypoxia \[[@CR9]\].

Whether the EPO levels in SA patients being changed or not remains controversial. Some studies demonstrated that EPO concentrations were no different between SA patients and normal subjects \[[@CR10], [@CR11]\]. In other studies, however, authors claimed that EPO levels were significantly increased in SA subjects \[[@CR12], [@CR13]\]. Furthermore, it has been suggested that continuous positive airway pressure (CPAP) treatment might normalize the diurnal EPO levels in SA patients \[[@CR14]\].

The primary aim of the present meta-analysis was to evaluate the EPO levels in SA patients via quantitatively analysis the present available literature.

Materials and methods {#Sec2}
=====================

The present meta-analysis was conducted following the guideline of the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) \[[@CR15]\].

Search strategy {#Sec3}
---------------

The electronic databases, namely PubMed, Embase, and Web of Science, were searched by using the following terms: *sleep apnea* OR *sleep-disorder breathing*, and *erythropoietin* from inception to May, 4, 2016. No language restrictions were applied. References from included studies were also perused.

Literature selection criteria {#Sec4}
-----------------------------

Two reviewers independently selected the available studies. Studies which met the following criteria were enrolled into the present meta-analysis: (1) participants included in the study were adults; (2) diagnosis of SA was according to polysomnography (PSG); (3) EPO levels were reported both in SA group and control group. Editorials, reviews, case reports, congress articles, and animal studies were excluded. An email to the corresponding author was written if the essential data of study was ambiguous or not presented. After two no response attempt, the study was also ruled out. The consensus was obtained through a meeting with all authors if any discrepancy were presented between the two reviewers.

Literature quality and data extraction {#Sec5}
--------------------------------------

Evidence level was defined in accordance with Oxford Centre for Evidence-based Medicine (CEBM)-Levels of Evidence \[[@CR16], [@CR17]\]. The data of the included articles were extracted by two reviewers independently. The following items were listed: first author, publication year, country, sample size, and the clinical characteristics of the participants, such as age, male percentage, body mass index (BMI), complications, PSG parameters and EPO levels in each group.

Statistical analysis {#Sec6}
--------------------

Stata version 12.0 and Review Manager 5.2 were applied for statistical analysis. The *I* ^2^ was obtained to express the heterogeneity between studies. If *I* ^2^ \> 50%, indicating that moderately or highly heterogeneous existed, a random effects model was conducted to estimate the effect size (Standard mean difference, SMD; 95% confidence interval, 95% CI); if *I* ^2^ ≤ 50%, fixed-effects model was used to obtain the weighted mean difference (WMD, 95% confidence interval, 95% CI) \[[@CR18]\]. Furthermore, subgroup analysis was performed to assess the influence of gender, BMI, AHI, cardiovascular disease, and time of exsanguinate blood on EPO levels. Since these variables of other type of SA \[[@CR19], [@CR20]\] and ODI value \[[@CR21], [@CR22]\], were only reported in two included studies, subgroup analysis were not performed stratified by these two variables. Sensitivity analysis was also conducted to evaluate the influence of each study on overall effect size. Potential publication bias was showed with funnel plot, and tested by Begg's test and Egger's test \[[@CR23]\]. Statistical significance was confirmed if *p* value \<0.05.

Results {#Sec7}
=======

Literature search {#Sec8}
-----------------

A total of 405 studies were identified by electronic search for initial scrutiny. After removing duplicated records and reviewing the titles and abstracts, 24 studies were considered worthy of further full-text scrutiny. Of the 24 studies, 15 studies were subsequently excluded (see detail in Fig. [1](#Fig1){ref-type="fig"}). Finally, 9 studies \[[@CR10]--[@CR13], [@CR19]--[@CR21], [@CR24], [@CR25]\] involving 407 participants were included into the present meta-analysis.

Fig. 1Study flow diagram

Characteristics of included studies {#Sec9}
-----------------------------------

Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} outline the characteristics of the subjects in each study. The evidence levels were 2b (both evidence levels and recommendation grade were moderate according to CEBM) in all studies. Sample size in each study was relatively small (less than 100). The predominant type of SA was obstructive sleep apnea (OSA) in most of the included studies. Except for one study, all SA patients in the included studies suffered severe SA (the apnea hypopnea index was more than 30 events/h). The exact EPO data in one study was obtained via contacting the corresponding author \[[@CR25]\].

Table 1Characteristics of included studiesStudy no.AuthorPublication yearCountryStudy designEvidence levelSample sizeSA groupControl group1McKeon1990AustraliaCross section2b23362Cahan1992USACross section2b1293Pokala1995USACross section2b884Imagawa2001JapanCross section2b41455Wang2004ChinaCross section2b18166Ryan2005IrelandCohort study2b19147Calvin2010ChileCross section2b14158Cifitci2011TurkeyCohort study2b69179Kukwa2013PolandCross section2b1423*SA* sleep apnea

Table 2Characteristics of included studiesStudy no.First authorAge (years, SA group/control group)Male (%, SA group/control group)BMI (kg/m^2^, SA group/control group)AHI (events/h, SA group/control group)ODI (events/h, SA group/control group)Type of SACardiovascular complicationsTime of exsanguinate blood for EPO detectionEPO (Mean ± SD)EPO unitSA groupControl group1McKeon52.8/56.088.4/81.031.9/29.233.8/3.4125/0.7OSANoEvening and morning11.8 ± 9.110.7 ± 7.1mU/ml2Cahan47/54100NA59/1.8NAOSAHypertensionMorning (8am)46 ± 3517 ± 8mU/ml3Pokala44.4/35.4100.0/62.542.9/36.850.8/2.2NAOSANAEvening (10 pm)21.2 ± 7.422.8 ± 7.3mU/ml4Imagawa^a^NANANA30--49/\<5NAOSANANA17 ± 2010 ± 5mU/ml5Wang^b^48/43100/100NA≥40/\<5NAOSANoMorning(5am)1.63 ± 0.261.47 ± 0.08ug/l6Ryan^c^39/40100/10032.5/31.048.5/1.046/2OSANoMorning(after PSG)13.4 ± 4.217.8 ± 12.5mU/ml7Calvin^d^65.7/59.993/5328.3/27.245.0/3.6NACSAHFMorning(post PSG)21.8 ± 9.116.5 ± 6.0mU/ml8Cifitci53.27/51.571.0/64.730.9/29.148.4/1.89NAOSANoMorning10.8 ± 6.09.7 ± 5.1NA9Kukwa^e^53.3/50.2100/10027.9/27.318.7/1.8NASDBAMINA24.3 ± 7.710.4 ± 3.2NA*SA* sleep apnea, *BMI* body mass index, *AHI* apena hypopnea index, *ODI* oxygen desaturation index, *EPO* Erythropoietin, *SD* stand deviation, *PSG* polysomnography, *NA* no available, *AMI* acute myocardial infarction^a^AHI\<5 in control group, AHI30-49 in OSA group^b^EPO data at 5:00 am were extracted^c^Exact EPO data was obtained by contacting the corresponding author via email^d^SDB group were all central sleep apnea patients^e^EPO data was extracted at day 1

Pool analysis of the difference in EPO between SA group and control group {#Sec10}
-------------------------------------------------------------------------

As the *I* ^2^ (80.2%) was significantly high, obviously heterogeneous existed between studies, thus random effect model was conducted to explore the difference in EPO between groups. Figure [2](#Fig2){ref-type="fig"} illustrates that EPO levels in the SA group were significantly higher than that in control group (SMD 0.61, 95% CI 0.11--1.11, *p* = 0.016).

Fig. 2Pool analysis of the difference in EPO between SA group and control group

Subgroup analysis stratified by various clinical parameters {#Sec11}
-----------------------------------------------------------

Table [3](#Tab3){ref-type="table"} outlines the subgroup analysis stratified by different parameters. Results showed that there were significantly higher EPO levels in patients with BMI \<30 kg/m^2^, and cardiovascular complications. EPO levels were increased in patients with SA regardless of AHI levels. Gender, and exsanguinate time had no influence on EPO in the further subgroup analysis.

Table 3Results of subgroup analysisSubgroupNo. of studyHeterogeneityWMD*I* ^2^*p*WMD (95% CI)*p*Gender Male470.40.0000.35 (−0.28--0.98)0.279 Male and female488.00.0000.93 (−0.22--2.08)0.111BMI ≥30 kg/m^2^ in OSA group Yes40.00.399−0.01 (−0.32--0.30)0.930 No280.30.0241.90 (0.57--3.24)0.005AHI ≥30 events/h Yes860.90.0120.38 (0.02--0.75)0.040 No1----2.61 (1.70--3.51)0.000Cardiovascular disease Yes370.80.0331.63 (0.71--2.55)0.001 No456.50.0750.16 (−0.30--0.61)0.501Time of exsanguinate blood Morning573.90.0040.53 (−0.09--1.14)0.092 Evening1----−0.22 (−1.2--0.77)0.664 Morning and evening1----0.14 (−0.39--0.66)0.604*WMD* weighted mean difference, *CI* confidence interval, *BMI* body mass index, *OSA* obstructive sleep apnea, *CSA* central sleep apnea, *SDB* sleep-disorder breathing

Sensitivity analysis {#Sec12}
--------------------

Sensitivity analysis showed that individual study had no influence on the overall effect size (Fig. [3](#Fig3){ref-type="fig"}).

Fig. 3Sensitivity analysis

Publication bias {#Sec13}
----------------

Figure [4](#Fig4){ref-type="fig"} shows that publication bias seem to exist, however, both Begg and Egger tests proved that no publication bias existed in the present study (*p* = 0.293 and 0.466, respectively).

Fig. 4Publication bias

Discussion {#Sec14}
==========

The present meta-analysis with 9 studies involving 407 participants demonstrated that, compared with normal subjects, EPO levels were increased in patients with SA, especially in those with low BMI, and cardiovascular complications.

EPO, a glycoprotein hormone with 30.4 kDa relative molecular mass, is composed of 165 amino acids. It is mainly produced by the kidney and liver in adult \[[@CR26]\]. EPO can bind to erythroid progenitor cell surface receptor, then leading to the activation of several signal pathways, such as the Ras/mitogen-activated kinase pathway, *etc* \[[@CR27]\]. After stimulation of certain genes expression, erythropoietic progenitor cells can proliferate and differentiate to mature red blood cells. The vital function of EPO is of regulation the blood oxygen levels via adjusting the circulating erythrocytes number \[[@CR26]\]. Diurnal variation of serum EPO levels can be detected in normal subjects: the nadir occurred at daytime, the peak concentration happened early in the morning, but this phenomenon could not be observed in chronic obstructive pulmonary disease \[[@CR28], [@CR29]\].

Serum levels of EPO can be influenced by various factors. The most important one is hypoxia. Evidence showed that elevated serum EPO levels are an adaptive response of human body to hypoxia. A previous study indicated that COPD patients, characterized by sustained hypoxia, had elevated serum EPO levels \[[@CR30]\]. The pathophysiological mechanism of intermittent hypoxia is similar to ischemia/reperfusion injury. Several studies indicated that pre-exposure to intermittent hypoxia can protect the myocardial tissue against ischemia/reperfusion injury \[[@CR31], [@CR32]\]. Similarly to sustained hypoxia, intermittent hypoxia has also been found to play a magnificent role in the regulation of EPO levels. An experimental study illustrated that EPO was increased significantly when rats were exposed to intermittent hypoxia for 1--3 weeks \[[@CR33]\]. The vital pathophysiological characteristic of SA is intermittent hypoxia. However, whether the EPO levels are increased or not in SA patients remained controversial. In addition, some interventional studies on the effect of CPAP treatment on EPO levels have shown contradictory results. Cahan et al. \[[@CR14]\] showed that CPAP treatment might attenuate diurnal EPO levels in SA patients. A study by Ryan and coworkers \[[@CR25]\] demonstrated that the EPO levels in OSA patients had no alternation after 6 weeks of CPAP treatment. Multicenter, randomized-control interventional study is needed to clarify the definitive effect of CPAP on EPO levels.

The subgroup analysis of the present study indicated that SA patients with cardiovascular disease had significantly higher EPO levels. We speculated that elevated EPO levels in patients with SA and cardiovascular disease were an adaptive response against intermittent hypoxia \[[@CR31]\]. Previous studies claimed that EPO levels had diurnal variation \[[@CR12], [@CR24]\]. The present meta-analysis was inconsistent with those studies, in that we could not observe the circadian fluctuation of EPO in SA patients. We also failed to explain the phenomenon that when compared to patients with high BMI, EPO was increased in patients with low BMI. The low numbers of included studies and small sample size might partly contribute to those phenomena. Further investigation is required to clarify those aforementioned phenomena.

Several limitations of the present meta-analysis should be emphasized. First, the most significant limitation was the severe heterogeneity between included studies, showing a high variation of the results among each study. Second, the individual study is relatively low-level evidence. Third, although a highly sensitive search strategy for the potentially eligible studies was applied, some studies may still be overlooked. Fourth, the relative small sample size of each included study might restrict the generalizability of the results. Fifth, except two included studies \[[@CR19], [@CR20]\] (subjects in one study was CSA, the other one was sleep-disorder breathing), subjects in the most remain studies were OSA, it was difficult for us to evaluate the influence of SA type on serum EPO levels. Finally, although statistical significance was not observed, it was still hard to rule out the publication bias.

In conclusion, the present meta-analysis confirmed that elevated EPO levels were found in SA patients. We speculated that increased EPO might be associated with increased risk of subsequent cardiovascular diseases in SA patients.
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